Clinical Trial Update: Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older [Phase 1]

View source ↗

Summary

A Phase 1 study of a vaccine candidate against respiratory syncytial virus, metapneumovirus, and parainfluenza virus type 3 in adults aged 60 and older has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metapneumovirus Infection
• Parainfluenza Virus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• RSV/Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Respiratory Syncytial Virus Infection, Metapneumovirus Infection | Phase 1 | Status: COMPLETED